Drug Safety

, Volume 24, Issue 1, pp 19–38 | Cite as

Anticancer Drug—Induced Kidney Disorders

Incidence, Prevention and Management
Review Article

Abstract

Nephrotoxicity is an inherent adverse effect of certain anticancer drugs. Renal dysfunction can be categorised as prerenal uraemia, intrinsic damage or postrenal uraemia according to the underlying pathophysiological process. Renal hypoperfusion promulgates prerenal uraemia. Intrinsic renal damage results from prolonged hypoperfusion, exposure to exogenous or endogenous nephrotoxins, renotubular precipitation of xenobiotics or endogenous compounds, renovascular obstruction, glomerular disease, renal microvascular damage or disease, and tubulointerstitial damage or disease. Postrenal uraemia is a consequence of clinically significant urinary tract obstruction. Clinical signs of nephrotoxicity and methods used to assess renal function are discussed.

Mechanisms of chemotherapy-induced renal dysfunction generally include damage to vasculature or structures of the kidneys, haemolytic uraemic syndrome and prerenal perfusion deficits. Patients with cancer are frequently at risk of renal impairment secondary to disease-related and iatrogenic causes.

This article reviews the incidence, presentation, prevention and management of anticancer drug-induced renal dysfunction. Dose-related nephrotoxicity subsequent to administration of certain chloroethylnitrosourea compounds (carmustine, semustine and streptozocin) is commonly heralded by increased serum creatinine levels, uraemia and proteinuria. Additional signs of streptozocin-induced nephrotoxicity include hypophosphataemia, hypokalaemia, hypouricaemia, renal tubular acidosis, glucosuria, aceturia and aminoaciduria. Cisplatin and carboplatin cause dose-related renal dysfunction. In addition to increased serum creatinine levels and uraemia, electrolyte abnormalities, such as hypomagnesaemia and hypokalaemia, are commonly reported adverse effects. Rarely, cisplatin has been implicated as the underlying cause of haemolytic uraemic syndrome. Pharmaceutical antidotes to cisplatin-induced nephrotoxicity include amifostine, sodium thiosulfate and diethyldithiocarbamate. Dose- and age-related proximal tubular damage is an adverse effect of ifosfamide. In addition to renal wasting of electrolytes, glucose and amino acids, Fanconi syndrome, rickets and osteomalacia have occurred with ifosfamide treatment.

High dose azacitidine causes renal dysfunction manifested by tubular acidosis, polyuria and increased urinary excretion of electrolytes, glucose and amino acids. Haemolytic uraemia is a rare adverse effect of gemcitabine. Methotrexate can cause increased serum creatinine levels, uraemia and haematuria. Acute renal failure is reported following administration of high dose methotrexate. Urinary alkalisation and hydration confer protection against methotrexate-induced renal dysfunction. Dose-related nephrotoxicity, including acute renal failure, are reported subsequent to treatment with pentostatin and diaziquone. Acute renal failure is a rare adverse effect of treatment with interferon-α. Haemolytic uraemic syndrome occurs with mitomycin administration. A mortality rate of 50 to 100% is reported in patients developing mitomycin—induced haemolytic uraemic syndrome. Capillary leak syndrome occurring with aldesleukin therapy can cause renal dysfunction. Infusion-related hypotension during infusion of high dose carmustine can precipitate renal dysfunction.

References

  1. 1.
    Fauci AS, Braunwald E, Isselbacher KJ, et al., editors. Harrison’s Principles of Internal Medicine. 14th ed. New York (NY): McGraw-Hill, 1998: 1504–11Google Scholar
  2. 2.
    Sutton TA, Molitoris BA. Mechanisms of cellular injury in ischemic acute renal failure. Semin Nephrol 1998; 18: 490–7PubMedGoogle Scholar
  3. 3.
    Foreman JW, Roth KS. Human renal Fanconi syndrome. Nephron 1989; 51: 301–6PubMedCrossRefGoogle Scholar
  4. 4.
    Goren MP, Pratt CB, Viar MJ. Tubular nephrotoxicity during long term ifosfamide and mesna therapy. Cancer Chemother Pharmacol 1989; 25: 70–2PubMedCrossRefGoogle Scholar
  5. 5.
    Goren MP, Wright RK, Horowitz ME, et al. Ifosfamide-induced subclinical tubular nephrotoxicity despite mesna. Cancer Treat Rep 1987; 71: 127–30PubMedGoogle Scholar
  6. 6.
    Grubb A. Diagnostic value of analysis of cystatin C and protein HC in biologic fluids. Clin Nephrol 1992; 38Suppl. 1: S20–S27PubMedGoogle Scholar
  7. 7.
    Johnsson A, Höglund P, Grubb A, et al. Cisplatin pharmacokinetics and pharmacodynamics in patients with squamous-cell carcinoma of the head/neck or esophagus. Cancer Chemother Pharmacol 1996; 39: 25–33PubMedCrossRefGoogle Scholar
  8. 8.
    Peterson PA, Evrin PE, Berggard I. Differentiation of glomerular, tubular, and normal proteinuria: determinations of urinary excretion of beta-2-microglobulin, albumin, and total protein. J Clin Invest 1969; 48: 1189–98PubMedCrossRefGoogle Scholar
  9. 9.
    Tokuc G, Yalciner A, Kebudi R, et al. Renal dysfunction secondary to ifosfamide treatment in children. J Exp Clin Cancer Res 1997; 16: 227–30PubMedGoogle Scholar
  10. 10.
    Daugaard G, Rossing N, Rørth M. Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose. Cancer Chemother Pharmacol 1988; 21: 163–7PubMedCrossRefGoogle Scholar
  11. 11.
    Hofman W, Rossmüller B, Guder WG, et al. A new strategy for characterizing proteinuria and haematuria fromsingle pattern of defined proteins in urine. Eur J Clin Chem Clin Biochem 1992; 30: 707–12Google Scholar
  12. 12.
    Skinner R, Pearson ADJ, Coulthard MG, et al. Assessment of chemotherapy-associated nephrotoxicity in children with cancer. Cancer Chemother Pharmacol 1991; 28: 81–92PubMedCrossRefGoogle Scholar
  13. 13.
    Whiting PH. The use of lithium clearance measurements as an estimate of glomerular-tubular function. Ren Fail 1999; 21: 421–6PubMedCrossRefGoogle Scholar
  14. 14.
    Bennett WM, Porter GA. Endogenous creatinine clearance as a clinical measure of glomerular filtration rate. BMJ 1971; 4: 84–6PubMedCrossRefGoogle Scholar
  15. 15.
    Breckenbridge A, Metcalfe-Gibson A. Methods of measuring glomerular filtration rate. Lancet 1965; II: 265–7CrossRefGoogle Scholar
  16. 16.
    Bjornsson TD. Use of serum creatinine concentrations to determine renal function. Clin Pharmacokinet 1979; 4: 200–22PubMedCrossRefGoogle Scholar
  17. 17.
    Davies DF, Shock NW. Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J Clin Invest 1950; 29: 496–504PubMedCrossRefGoogle Scholar
  18. 18.
    Dentino M, Luft FC, Yum MN, et al. Long term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man. Cancer 1978; 41: 1274–81PubMedCrossRefGoogle Scholar
  19. 19.
    Womer RB, Pritchard J, Barratt TM. Renal toxicity of cisplatin in children. J Pediatr 1985; 106: 659–63PubMedCrossRefGoogle Scholar
  20. 20.
    De Vita VT, Hellman S, Rosenberg SA, editors. Cancer: Principles and practice of oncology. 5th ed. Philadelphia (PA): Lippincott, 1997: 2369–73, 2494-5, 2486Google Scholar
  21. 21.
    Rutlan MD, Que L. A comparison of the renal handling of 99Tcm-DTPA and 99Tcm-MAG3 in hypertensive patients using an uptake technique. Nuclear Med Comm 1999; 20: 823–8CrossRefGoogle Scholar
  22. 22.
    Schrier MD, Gottschalk CW, editors. Diseases of the kidney. 4th ed. Boston(MA): Little, Brown and Company, 1988: 65Google Scholar
  23. 23.
    Remuzzi G, Ruggenenti P. The hemolytic uremic syndrome. Kidney Int 1998; 66Suppl.: S54–S57Google Scholar
  24. 24.
    Tannock IF, Hill RP. The basic science of oncology. New York (NY): Paragon Press, 1992: 16–7Google Scholar
  25. 25.
    Hanlon JT, Ruby CM, Shelton PS, et al. Geriatrics. In: DiPiro JT, Talbert RL, Yee GC, et al. Stamford (CT): Appleton & Lange, 1999: 52–61Google Scholar
  26. 26.
    Fetterman GH, Shuplock NA, Philipp FJ, et al. The growth and maturation of human glomeruli and proximal convolutions from term top adulthood. Pediatrics 1965; 35: 601–19PubMedGoogle Scholar
  27. 27.
    Hua MJ, Kun HY, Jie CS, et al. Urinary microalbumin and retinol-binding protein assay for verifying children’s nephron development andmaturation. Clin Chim Acta 1997; 264: 127–32PubMedCrossRefGoogle Scholar
  28. 28.
    Skinner R, Pearson ADJ, Price L, et al. The influence of age on nephrotoxicity following chemotherapy in children. Br J Cancer 1992; 66Suppl. 18: S30–S5Google Scholar
  29. 29.
    Breen D, Bihari D. Acute renal failure as a part of multiple organ failure: the slippery slope of critical illness. Kidney Int 1998; 66Suppl.: S25–S33Google Scholar
  30. 30.
    Micetech KC, Jensen-Akula M, Mandard JC, et al. Nephrotoxicity of semustine (methyl-CCNU) in patients with malignant melanoma receiving adjuvant chemotherapy.Am J Med 1981; 71: 967–72CrossRefGoogle Scholar
  31. 31.
    Schacht RG, Feiner HD, Gallo GR, et al.967-72 Nephrotoxicity of the nitrosoureas. Cancer 1981; 48: 1328–34PubMedCrossRefGoogle Scholar
  32. 32.
    Weiss RB, Posada JG, Kramer RA, et al. Nephrotoxicity of semustine. Cancer Treat Rep 1983; 67: 1105–12PubMedGoogle Scholar
  33. 33.
    Harmon WE, Cohen HJ, Schneeberger WE, et al. Chronic renal failure in children treated with methyl CCNU. N Engl J Med 1979; 300: 1200–3PubMedCrossRefGoogle Scholar
  34. 34.
    Perry DJ, Weiss RB. Nephrotoxicity of streptozocin [letter]. Ann Intern Med 1982; 96: 122PubMedGoogle Scholar
  35. 35.
    Sadoff L. Nephrotoxicity of streptozocin (NSC-85998). Cancer Chemother Rep 1970; 54: 457–9PubMedGoogle Scholar
  36. 36.
    Silver HKB, Morton DL. CCNU nephrotoxicity following sustained remission in oat cell carcinoma. Cancer Treat Rep 1979; 63: 226–7PubMedGoogle Scholar
  37. 37.
    Kramer RA, McMenamin MG, Boyd MR. In vivo studies on the relationship between hepatic metabolism and the renal toxicity of 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea (MeCCNU). Toxicol Appl Pharmacol 1986; 85: 221–30PubMedCrossRefGoogle Scholar
  38. 38.
    Fichtinger-Schepman AMJ, van Oosterom AT, Lohman PMH, et al. cis-diamminedichloroplatinum(II) induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum( II). Cancer Res 1987; (47): 3000–4PubMedGoogle Scholar
  39. 39.
    Rosenberg B. Possible mechanisms for the antitumor activity of platinum coordination complexes. Cancer Chemother Rep 1975; 59: 589–98PubMedGoogle Scholar
  40. 40.
    Gaver RC, George AM, Deeb G. In vitro stability, plasma protein binding and blood cell partitioning of 14C-carboplatin. Cancer Chemother Pharmacol 1987; 20: 271–6PubMedCrossRefGoogle Scholar
  41. 41.
    Micetich KC, Barnes D, Erickson LC. A comparative study of the cytotoxicity and DNA-damaging effects of cis-(diammino)( 1,1-cyclobutanedicarboxylato)-platinum(II) and cisdiamminedichloroplatinum( II) on L1210 cells. Cancer Res 1985; 45: 4043–7PubMedGoogle Scholar
  42. 42.
    Higby DJ, Wallace HJ, Hollard JF, et al. Cis-diamminedichloroplatinum (NSC-119875): a phase I study. Cancer Chemother Rep 1973; 57: 459–63PubMedGoogle Scholar
  43. 43.
    Beyer J, Rick O, Weinknecht S, et al. Nephrotoxicity after high-dose carboplatin, etoposide, and ifosfamide in germcell tumors: incidence and implications for hematologic recovery and clinical outcome. Bone Marrow Transplant 1997; 20: 813–9PubMedCrossRefGoogle Scholar
  44. 44.
    Shea TC, Flaherty M, Elias A, et al. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol 1989; 7: 651–61PubMedGoogle Scholar
  45. 45.
    Macleod PM, Tyrell CJ, Keeling DH. The effect of cisplatin on renal function in patients with testicular tumors. Clin Radiol 1988; 39: 190–2PubMedGoogle Scholar
  46. 46.
    Daugaard G, Abildgaard U, Holstein-Rathlou N-H, et al. Renal tubular function in patients treated with high-dose cisplatin. Clin Pharmacol Ther 1988; 44: 164–72PubMedCrossRefGoogle Scholar
  47. 47.
    Yamamato N, Tamura T, Maeda M, et al. The influence of ageing on cisplatin pharmacokinetics in lung cancer patients with normal renal function. Cancer Chemother Pharmacol 1995; 36: 102–6CrossRefGoogle Scholar
  48. 48.
    Ariceta G, Rodriguez-Soriano J, Vallo A, et al. Acute and chronic effects of cisplatin therapy on renal magnesium homeostasis. Med Pediatr Oncol 1997; 28: 25–40CrossRefGoogle Scholar
  49. 49.
    Bianchetti MG, Kanaka C, Ridolfi-Lüthy A, et al. Chronic renal magnesium loss, hypocalciuria and mild hypokalaemic metabolic alkalosis after cisplatin. Pediatr Nephrol 1990; 4: 219–22PubMedCrossRefGoogle Scholar
  50. 50.
    Buckley JE, Clark VL, Meyer TJ, et al. Hypomagnesemia after cisplatin combination chemotherapy. Arch Intern Med 1984; 144: 2347–8PubMedCrossRefGoogle Scholar
  51. 51.
    Al-Sarraf M, Fletcher W, Oishi N, et al. Cisplatin hydrationwith and without mannitol diuresis in refractory disseminated malignant melanoma. A Southwest Oncology Group study. Cancer Treat Rep 1982; 66: 31–5PubMedGoogle Scholar
  52. 52.
    Hayes DM, Cvitkovic E, Golbey RB, et al. High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer 1977; 39: 1372–81PubMedCrossRefGoogle Scholar
  53. 53.
    Pizani V, Bressolle F, Haug IJ, et al. Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review. Cancer Chemother Pharmacol 1994; 35: 1–9CrossRefGoogle Scholar
  54. 54.
    Daugaard G. Cisplatin nephrotoxicity: experimental and clinical studies. Dan Med Bull 1990; 37: 1–12PubMedGoogle Scholar
  55. 55.
    Dumas M, De Gislain C, d’Athis P, et al. Influence of hydration on ultrafilterable platinum kinetics and kidney function in patients treated with cis-diamminedichloroplatinum(II). Cancer Chemother Pharmacol 1990; 26: 278–82PubMedCrossRefGoogle Scholar
  56. 56.
    Ozols RF, Corden BJ, Jacob J, et al. High-dose cisplatin in hypertonic saline. Ann Intern Med 1984; 100: 19–24PubMedGoogle Scholar
  57. 57.
    Belt RJ, Himmelstein KJ, Patton TF, et al. Pharmacokinetics of nonprotein-bound platinum species following administration of cis-diamminedichloroplatinum(II). Cancer Treat Rep 1979; 63: 1515–21PubMedGoogle Scholar
  58. 58.
    Jacobs C, Bertino JR, Goffinet DR, et al. 24 hour infusion of cis-platinum in head and neck cancers. Cancer 1978; 42: 2135–40PubMedCrossRefGoogle Scholar
  59. 59.
    Salem P, Khalyl M, Jabboury K, et al. Cis-diammedichloroplatinum( II) by 5-day continuous infusion: a new dose schedule with minimal toxicity. Cancer 1984; 55: 837–40CrossRefGoogle Scholar
  60. 60.
    Shaw LM, Turrisi AT, Glover DJ, et al. Human pharmacokinetics of WR2721. Int J Radiat Oncol Biol Phys 1986; 12: 1501–4PubMedCrossRefGoogle Scholar
  61. 61.
    Yuhas JM, Davis ME, Glover D, et al. Circumvention of the tumormembrane barrier to WR-2721 absorption by reduction of drug hydrophilicity. Int J Radiat Oncol Biol Phys 1982; 8: 519–22PubMedCrossRefGoogle Scholar
  62. 62.
    Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatininduced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996; 14: 2101–12PubMedGoogle Scholar
  63. 63.
    Schiller JH, Storer B, Berlin J, et al. Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival. J Clin Oncol 1996; 14: 1913–21PubMedGoogle Scholar
  64. 64.
    Tannehill SP, Mehta MP, Larson M, et al. Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial. J Clin Oncol 1997; 15: 2850–7PubMedGoogle Scholar
  65. 65.
    Pfeifle CE, Howell SB, Felthouse RD, et al. High-dose cisplatin with sodium thiosulfate protection. J Clin Oncol 1987; 3: 237–44Google Scholar
  66. 66.
    Howell SB, Pfeifle CE, Wung WE, et al. Intraperitoneal cis-diamminedichloroplatinum with systemic sodium thiosulfate. Cancer Res 1983; 43: 1426–31PubMedGoogle Scholar
  67. 67.
    Elferink F, van der Vijgh WJF, Pinedo HM. Interaction of cisplatin and carboplatin with sodium thiosulfate: reaction rates and protein binding. Clin Chem 1986; 32: 641–5PubMedGoogle Scholar
  68. 68.
    Markman M, Cleary S, Howell SB. Nephrotoxicity of high-dose intracavitary cisplatinwith intravenous thiosulfate protection. Eur J Cancer Clin Oncol 1985; 21: 1015–8PubMedCrossRefGoogle Scholar
  69. 69.
    Menczer J, Ben-Baruch G, Rizel S, et al. Acute renal failure associated with intraperitoneal cisplatin chemotherapy with systemic thiosulfate protection in ovarian cancer patients. Eur J Gynecol Oncol 1991; 12: 403–6Google Scholar
  70. 70.
    Berry JM, Jacobs C, Sikic B, et al. Modification of cisplatin toxicity with diethyldithiocarbamate. J Clin Oncol 1990; 8: 1585–90PubMedGoogle Scholar
  71. 71.
    Qazi R, Chang AY, Borch RF, et al. Phase I clinical and pharmacokinetic study of diethyldithiocarbamate as a protector from toxic effects of cisplatin. J Natl Cancer Inst 1988; 80: 1486–8PubMedCrossRefGoogle Scholar
  72. 72.
    Baldwin GS, McVie JG, Van Der Valk MA, et al. Selective reduction in the cis-diamminedichloroplatinum(II) nephrotoxicity be ebselen. Cancer Res 1990; 50: 7031–6Google Scholar
  73. 73.
    Tokunaga J, Kobayashi M, Kitagawa A, et al. Protective effects of betamipron on renal toxicity during repeated cisplatin administration in rats and protective mechanism. Ren Fail 1998; 20: 27–38PubMedCrossRefGoogle Scholar
  74. 74.
    Bishop JF. Current experience with high-dose carboplatin therapy. Semin Oncol 1992; 19Suppl. 2: 150–4PubMedGoogle Scholar
  75. 75.
    Broun ER, Nichols CR, Mandanas R, et al. Dose escalation study of high-dose carboplatin and etoposide with autologous bone marrow support in patients with recurrent and refractory germ cell tumors. Bone Marrow Transplant 1995; 16: 353–8PubMedGoogle Scholar
  76. 76.
    Elias AD, Ayash LJ, Eder JP, et al. Aphase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support. J Clin Oncol 1991; 9: 320–7PubMedGoogle Scholar
  77. 77.
    Lotz JP, Machover D, Malassagne B, et al. Phase I-II study of two consecutive courses of high-dose epipodophyllotoxin, ifosfamide, and carboplatin with autologous bone marrow transplantation for treatment of adult patients with solid tumors.J Clin Oncol 1991; 9: 1860–70PubMedGoogle Scholar
  78. 78.
    Schilder RJ, Johnson S, Gallo J, et al. Phase I trial of multiple cycles of high-dose chemotherapy supported by autologous peripheral-blood stem cells. J Clin Oncol 1999; 17: 2198–207PubMedGoogle Scholar
  79. 79.
    Wandt H, Birkmann J, Denzel Th, et al. Sequential cycles of high-dose chemotherapy with dose escalation of carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral blood progenitor cells: a phase I/II study in advanced ovarian cancer. Bone Marrow Transplant 1999; 23: 763–70PubMedCrossRefGoogle Scholar
  80. 80.
    Wilson WH, Jain V, Bryant G, et al. Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors. J Clin Oncol 1992; 10: 1712–22PubMedGoogle Scholar
  81. 81.
    Pico JL, Ibrahim A, Castagna L, et al. Escalating high-dose carboplatin and autologous bone marrow transplantation in solid tumors. Oncology 1993; 50Suppl. 2: 47–52PubMedCrossRefGoogle Scholar
  82. 82.
    English MW, Skinner R, Pearson ADJ, et al. Dose-related nephrotoxicity of carboplatin in children. Br J Cancer 1999; 81: 336–41PubMedCrossRefGoogle Scholar
  83. 83.
    Newell DR, Pearson ADJ, Balmanno K, et al. Carboplatin pharmacokinetics in children; the development of a pediatric dosing formula. J Clin Oncol 1995; 11: 2314–23Google Scholar
  84. 84.
    Gordon SJ, Pearson ADJ, Reid MM, et al. Toxicity of single-day high-dose vincristine, melphalan, etoposide and carboplatin consolidation with autologous bone marrow rescue in advanced neuroblastoma. Eur J Cancer 1992; 28A: 1319–23PubMedCrossRefGoogle Scholar
  85. 85.
    Corbett R, Pinkerton C, Pritchard J, et al. Pilot study of high dose vincristine, etoposide, carboplatin, and melphalan with autologous bone marrow rescue in advanced neuroblastoma. Eur J Cancer 1992; 28A: 1324–8PubMedCrossRefGoogle Scholar
  86. 86.
    Canoplat C, Pearson P, Jaffe N. Cisplatin-associated hemolytic uremic syndrome. Cancer 1994; 74: 3059–62CrossRefGoogle Scholar
  87. 87.
    Jackson AM, Rose BD, Graff LG, et al. Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann Intern Med 1984; 101: 41–4PubMedGoogle Scholar
  88. 88.
    Van Der Meer J, De Vries EGE, Vriesendorp R, et al. Hemolytic uremic syndrome in a patient on cis-platinum, vinblastine and bleomycin. J Cancer Res Clin Oncol 1985; 110: 119–22PubMedCrossRefGoogle Scholar
  89. 89.
    Weinblatt ME, Kahn E, Scimeca PG, et al. Hemolytic uremic syndrome associated with cisplatin therapy. Am J Pediatr Hematol Oncol 1987; 9: 295–8PubMedCrossRefGoogle Scholar
  90. 90.
    Dorr RT, Von Hoff DD. Chemotherapy handbook. 2nd ed. Norwalk (CT): Appleton & Lange, 1994: 559–60Google Scholar
  91. 91.
    Pratt CB, Meyer WH, Jenkins JJ, et al. Ifosfamide, Fanconi’s syndrome, and rickets. J Clin Oncol 1991; 9: 1495–9PubMedGoogle Scholar
  92. 92.
    Willemse PH, De Jong PE, Elema JD, et al. Severe renal failure following high-dose ifosfamide and mesna. Cancer Chemother Pharmacol 1989; 23: 329–30PubMedCrossRefGoogle Scholar
  93. 93.
    Martinez F, Deray G, Cacoub P, et al. Ifosfamide nephrotoxicity: deleterious effect of previous cisplatin administration. Lancet 1996; 348: 1100–1PubMedCrossRefGoogle Scholar
  94. 94.
    Skinner R, Sharkey IM, Pearson DJ, et al. Ifosfamide, mesna, and nephrotoxicity in children. J Clin Oncol 1993; 11: 173–90PubMedGoogle Scholar
  95. 95.
    Goren MP, Wright RK, Pratt CB, et al. Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy. Cancer Res 1987; 47: 1457–60PubMedGoogle Scholar
  96. 96.
    Loebstein R, Atanackovic G, Bishai R, et al. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children. J Clin Pharmacol 1999; 39: 454–1PubMedGoogle Scholar
  97. 97.
    Koch Nogueira PC, Hadj-Aissa A, Schell M, et al. Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma. Pediatr Nephrol 1998; 12: 572–5PubMedCrossRefGoogle Scholar
  98. 98.
    English MW, Skinner R, Pearson ADJ, et al. The influence of ifosfamide scheduling on acute nephrotoxicity in children. Br J Cancer 1997; 75: 1356–9PubMedCrossRefGoogle Scholar
  99. 99.
    Arndt C, Morgenstern B, Hawkins D, et al. Renal function following combination chemotherapy with ifosfamide and cisplatin in patients with osteogenic sarcoma. Med Pediatr Oncol 1999; 32: 93–6PubMedCrossRefGoogle Scholar
  100. 100.
    Heney D, Wheeldon J, Rushworth P, et al. Progressive real toxicity due to ifosfamide. Arch Dis Child 1991; 66: 966–70PubMedCrossRefGoogle Scholar
  101. 101.
    Moncrieff M, Foot A. Fanconi syndrome after ifosfamide. Cancer Chemother Pharmacol 1989; 23: 121–2PubMedCrossRefGoogle Scholar
  102. 102.
    Burk CD, Restaino I, Kaplan BS, et al. Ifosfamide-induced renal tubular dysfunction and rickets in children with Wilm’s tumor. J Pediatr 1990; 117: 331–5PubMedCrossRefGoogle Scholar
  103. 103.
    Newbury-Ecob, Noble VW, Barbor PR. Ifosfamide-induced Fanconi syndrome [letter]. Lancet 1989; I: 1328CrossRefGoogle Scholar
  104. 104.
    De Schepper J, Stevens G, Verboven M, et al. Ifosfamide-induced Fanconi’s syndrome with growth failure in a 2-year old child. Am J Pediatr Hematol Oncol 1991; 13: 39–41PubMedCrossRefGoogle Scholar
  105. 105.
    Saurez A, McDowell H, Niaudet P, et al. Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an international society of pediatric oncology report. J Clin Oncol 1991; 9: 2177–82Google Scholar
  106. 106.
    Rossi R, Pleyer J, Schafer P. et al. Development of ifosfamide-induced nephrotoxicity: prospective follow-up in 75 patients. Med Pediatr Oncol 1999; 32: 177–82PubMedCrossRefGoogle Scholar
  107. 107.
    Ashraf MS, Skinner R, English MW, et al. Late reversibility of chronic ifosfamide-associated nephrotoxicity in a child. Med Pediatr Oncol 1997; 28: 62–4PubMedCrossRefGoogle Scholar
  108. 108.
    Whittington RM, Close HP. Clinical experience with mitomycin C (NSC-26980). Cancer Treat Rep 1970; 54: 195–8Google Scholar
  109. 109.
    Wise GR, Kuhn IN, Godfrey TE. Mitomycin C in large infrequent doses in breast cancer. Med Pediatr Oncol 1976; 2: 55–60PubMedCrossRefGoogle Scholar
  110. 110.
    Cantrell JE, Phillips TM, Schein PS. Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy. J Clin Oncol 1985; 3: 723–34PubMedGoogle Scholar
  111. 111.
    Gulati SC, Sordillo P, Kempin S, et al. Microangiopathic anemia observed after treatment of epidermoid carcinoma with mitomycin C and 5-fluorouracil. Cancer 1980; 45: 2252–7PubMedCrossRefGoogle Scholar
  112. 112.
    Hamner RW, Verani R, Weinman EJ. Mitomycin-associated renal failure. Arch Intern Med 1983; 143: 803–7PubMedCrossRefGoogle Scholar
  113. 113.
    Hanna WT, Krauss S, Regester RF, et al. Renal disease after mitomycin C therapy. Cancer 1981; 48: 2583–8PubMedCrossRefGoogle Scholar
  114. 114.
    Jolivet J, Giroux L, Laurin S, et al. Microangiopathic hemolytic anemia, renal failure, and noncardiogenic pulmonary edema: a chemotherapy-induced syndrome. Cancer Treat Rep 1983; 67: 429–34PubMedGoogle Scholar
  115. 115.
    Jones BG, Fielding JW, Newman CE, et al. Intravascular haemolysis and renal impairment after blood transfusion in two patients on long-term 5-fluorouracil and mitomycin C. Lancet 1980; I: 1275–7CrossRefGoogle Scholar
  116. 116.
    Lesesne JB, Rothschild N, Erickson B, et al. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol 1989; 7: 781–9PubMedGoogle Scholar
  117. 117.
    Liu K, Mittelman A, Sproul EE, et al. Renal toxicity in man treated with mitomycin C. Cancer 1971; 5: 1314–20CrossRefGoogle Scholar
  118. 118.
    Rabadi SJ, Khandeker JD, Miller HJ. Mitomycin-induced hemolytic uremic syndrome: case presentation and reviewof the literature. Cancer Treat Rep 1982; 66: 1244–7PubMedGoogle Scholar
  119. 119.
    Dorr RT, Von Hoff DD. Chemotherapy handbook. 2nd ed. Norwalk (CT): Appleton & Lange, 1994: 268, 699–701, 774-5Google Scholar
  120. 120.
    Peterson BA, Collins AJ, Vogelzang NJ, et al. 5-azacytidine and renal tubular dysfunction. Blood 1981; 57: 182–5PubMedGoogle Scholar
  121. 121.
    Fung MC, Storniolo AM, Nguyen B, et al. A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer 1999; 85: 2023–32PubMedGoogle Scholar
  122. 122.
    Weinblatt ME. Toxicity of low dose methotrexate in rheumatoid arthritis. J Rheumatol 1985; 12Suppl. 12: 35–9Google Scholar
  123. 123.
    Fox RM. Methotrexate nephrotoxicity. Clin Exp Pharmacol Physiol 1979; 5: 43–5PubMedGoogle Scholar
  124. 124.
    Frei E, Jaffe N, Tattersall MH, et al. New approaches to cancer chemotherapy with methotrexate. N Engl J Med 1975; 292: 846–51PubMedCrossRefGoogle Scholar
  125. 125.
    Howell SB, Carmody J. Changes in glomerular filtration rate associated with high-dose methotrexate therapy in adults. Cancer Treat Rep 1977; 61: 1389–91PubMedGoogle Scholar
  126. 126.
    Price P, Thompson H, Bessell EM, et al. Renal impairment following the combined use of high-dose methotrexate and procarbazine. Cancer Chemother Pharmacol 1988; 21: 265–7PubMedCrossRefGoogle Scholar
  127. 127.
    Thierry FX, Vernier I, Dueymes JM, et al. Acute renal failure after high-dose methotrexate therapy. Role of hemodialysis and plasma exchange in methotrexate removal [letter]. Nephron 1989; 51: 416–7PubMedCrossRefGoogle Scholar
  128. 128.
    Ries F, Klastersky J. Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kid Dis 1986; 8: 368–79PubMedGoogle Scholar
  129. 129.
    Goldberg ID, Garnick MB, Bloomer WD. Urinary tract toxic effects of cancer therapy. J Urol 1984; 132: 1–6PubMedGoogle Scholar
  130. 130.
    Pittman SW, Frei E. Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin’s lymphoma. Cancer Treat Rep 1977; 61: 695–701Google Scholar
  131. 131.
    Grever MR, Bisaccia E, Scarborough DA, et al. An investigation of 2’-deoxycoformycin in the treatment of cutaneous T-cell lymphoma. Blood 1983; 61: 279–82PubMedGoogle Scholar
  132. 132.
    Major PP, Agarwal RP, Kufe DW. Clinical pharmacology of deoxycoformycin. Blood 1981; 58: 91–6PubMedGoogle Scholar
  133. 133.
    Riley MR, Hebel SK, Burnham TH, et al. Drug facts and comparisons. St Louis, (MO): Facts and Comparisons, 1999: 1861, 1880Google Scholar
  134. 134.
    Lee EJ, Van Echo DA, Egorin MJ, et al. Diaziquone given as a continuous infusion is an active agent for relapsed adult acute nonlymphocytic leukemia. Blood 1986; 67: 182–7PubMedGoogle Scholar
  135. 135.
    Schulman P, Davis R, Lee E, et al. Phase II study of continuous infusion diaziquone in relapsed/ refractory acute nonlymphocytic leukemia. Cancer Treat Rep 1987; 71: 755–7PubMedGoogle Scholar
  136. 136.
    Stiff PJ, McKenzie RS, Potempa LD, et al. A phase I trial of high-dose diaziquone and autologous bone marrow transplantation: an Illinois Cancer Council study. J Clin Oncol 1991; 9: 1487–94PubMedGoogle Scholar
  137. 137.
    Quesada JR, Talpaz M, Rios A, et al. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 1986; 4: 234–43PubMedGoogle Scholar
  138. 138.
    Jone GJ, Itri LM. Safety and tolerance of recombinant interferon alfa-2α (Roferon-A) in cancer patients. Cancer 1986; 57Suppl.: 1709–15CrossRefGoogle Scholar
  139. 139.
    Coroneos E, Petrusevska G, Varghese F, et al. Focal segmental glomerulosclerosis with acute renal failure associated with a-interferon therapy. Am J Kidney Dis 1996; 28: 888-92Google Scholar
  140. 140.
    Dimitrov Y, Heibel F, Marcellin L, et al. Acute renal failure and nephrotic syndrome with alpha interferon therapy. Nephrol Dial Transplant 1997; 12: 200–3PubMedCrossRefGoogle Scholar
  141. 141.
    Nassar GM, Pedro P, Remmers RE, et al. Reversible renal failure in a patient with the hypereosinophilia syndrome during therapywith alpha interferon. Am J Kidney Dis 1998; 31: 121–6PubMedCrossRefGoogle Scholar
  142. 142.
    Miranda-Guardiola F, Fdez-Llama P, Badia JR, et al. Acute renal failure associated with alpha-interferon therapy for chronic hepatitis B. Nephrol Dial Transplant 1995; 10: 1441–3PubMedGoogle Scholar
  143. 143.
    Kurschel E, Metz-Kurschel V, Niederle N, et al. Investigations on the subclinical and clinical nephrotoxicity of interferon alpha-2B in patients with myeloproliferative syndromes. Ren Fail 1991; 13: 87–93PubMedCrossRefGoogle Scholar
  144. 144.
    Kozeny GA, Nicolas JD, Creekmore S, et al. Effects of interleukin- 2 immunotherapy on renal function. J Clin Oncol 1988; 6: 1170–6PubMedGoogle Scholar
  145. 145.
    Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and IL-2 or high dose IL-2 alone. N Engl J Med 1987; 316: 889–97PubMedCrossRefGoogle Scholar
  146. 146.
    Textor SC, Margolin K, Blayney D, et al. Renal, volume, and hormonal changes during therapeutic administration of recombinant interleukin-2 in man. Am J Med 1987; 83: 1055–61PubMedCrossRefGoogle Scholar
  147. 147.
    Kruit WH, Schmitz PI, Stoter G. The role of possible risk factors for acute and late renal dysfunction after high-dose interleukin- 2, interferon alpha and lymphokine-activated killer cells. Cancer Immunol Immunother 1999; 48: 331–5PubMedCrossRefGoogle Scholar
  148. 148.
    Belldegrun A, Webb DE, Austin HE, et al. Effects of interleukin- 2 on renal function in patients receiving immunotherapy for advanced cancer. Ann Intern Med 1987; 106: 817–22PubMedGoogle Scholar
  149. 149.
    Lotze MT, Matory YL, Rayner AA, et al. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 1986; 58: 2764–72PubMedCrossRefGoogle Scholar
  150. 150.
    Phillips GL, Fay JW, Herzig GP, et al. Intensive BCNU (1,3- bis(2-chloroethyl)-1-nitrosourea, NSC 409962) and autologous bone marrow transplantation for refractory cancer. A phase I-II study. Cancer 1983; 52: 1792–802PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  1. 1.Department of PharmacyHarper Hospital, Barbara Ann Karmanos Cancer Institute, Wayne State UniversityDetroitUSA

Personalised recommendations